Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment.
Latest Information Update: 06 Oct 2022
At a glance
- Drugs Interferon alpha-2a (Primary) ; Infliximab
- Indications Behcet's syndrome
- Focus Therapeutic Use
- Acronyms BIO BEHCET'S
- 01 Jul 2021 Status changed from active, no longer recruiting to completed.
- 10 Nov 2020 Planned End Date changed from 6 Nov 2020 to 30 Jun 2021.
- 09 Jan 2020 Status changed from recruiting to active, no longer recruiting.